Results
The total number of fetal records during 2011–2014 within the JECS was 104,102. A total of 86,370 participants met the inclusion criteria (Figure 1). Among them, 5,354 participants had uterine myomas (myoma group), while the remaining 81,016 were the participants without uterine myomas (control group).
Table 1 summarizes clinical and demographic characteristics, and obstetric outcomes. Except for II, the incidence of APOs was higher in the myoma group than in the control group.
The aORs of PTB before 37, and 34 weeks, pPROM, II, and GH in the myoma group were 1.37 (95% confidence interval [CI], 1.22–1.54), 1.61 (95% CI, 1.27–2.05), 1.65 (95% CI, 1.33–2.04), 1.05 (95% CI, 0.75–1.46), and 1.20 (95% CI, 1.05–1.38), respectively. The aORs of PTB, pPROM, and GH were significantly higher in the myoma group than that in control group (Table 2).
The aORs of PTB and pPROM in women with II and uterine myomas were 1.81 (95% CI, 0.64–5.15) and 1.29 (95% CI, 0.17–9.54), while the aORs of PTB and pPROM in women with II without uterine myomas were 3.16 (95% CI, 2.39–4.19) and 5.54 (95% CI, 3.72–8.25), respectively. Although the aORs of PTB and pPROM were significantly increased in women with II without uterine myomas, the aORs were not significantly increased in women with II and uterine myomas (Table 3).